Pathogenesis of vasculopathy in systemic sclerosis and its contribution to fibrosis

Curr Opin Rheumatol. 2023 Nov 1;35(6):309-316. doi: 10.1097/BOR.0000000000000959. Epub 2023 Jul 24.

Abstract

Purpose of review: In patients with systemic sclerosis (SSc), vascular manifestations precede skin and organ fibrosis. There is increasing evidence demonstrating a pathogenic link between early vascular injury and subsequent development of tissue fibrosis.

Recent findings: Our knowledge of cellular and molecular mechanisms underlying a unique relationship between SSc-related vasculopathy and fibrosis has changed over the last few years. There is increasing evidence showing viral infection as a potential trigger elucidating vascular injury. Due to defective vascular repair machinery, this initial event results in endothelial cell activation and apoptosis as well as the recruitment of inflammatory/immune cells, leading to endothelial-to-mesenchymal transition. This sequential process induces destructive vasculopathy in capillaries, fibroproliferative vascular lesions in arteries, and excessive fibrosis in the surrounding tissue. A variety of molecular mechanisms and pathways involved in vascular remodeling linked to subsequent excessive fibrosis have been identified and serve as attractive therapeutic targets for SSc.

Summary: Endothelial injury may play a central role in connecting three features that characterize SSc pathogenesis: vasculopathy, chronic inflammation, and fibrosis. Our understanding of the processes responsible for myofibroblast differentiation triggered by vascular injury will provide the rationale for novel targeted therapies for SSc.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Fibrosis
  • Humans
  • Inflammation / drug therapy
  • Scleroderma, Systemic* / complications
  • Scleroderma, Systemic* / drug therapy
  • Vascular Diseases*
  • Vascular System Injuries*